drugset / Trial / NCT07396337

Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.

NCT07396337

Phase 2 Recruiting 320 enrolled Changzhou Qianhong Bio-pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of QHRD106 injection in treating acute ischemic stroke.

Timeline

Start
2026-01-19
Primary completion
2026-10-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject QHRD106 Unknown 5600 iu Intravenous
Subject QHRD106 Unknown 8400 iu Intravenous
Subject QHRD106 Unknown 12600 iu Intravenous

Indications